CIPLA
|
CIPLA Last 5 Year Financial Ratios History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Operational & Financial Ratios | |||||
Earnings Per Share (Rs) | 51.05 | 34.71 | 31.19 | 29.82 | 19.18 |
CEPS(Rs) | 64.49 | 49.65 | 44.76 | 43.02 | 33.76 |
DPS(Rs) | 13.00 | 8.50 | 5.00 | 5.00 | 4.00 |
Book NAV/Share(Rs) | 329.72 | 289.24 | 257.78 | 226.73 | 194.85 |
Tax Rate(%) | 27.12 | 29.79 | 26.73 | 27.01 | 28.98 |
Margin Ratios | |||||
Core EBITDA Margin(%) | 17.76 | 16.13 | 15.18 | 15.05 | 11.72 |
EBIT Margin(%) | 16.35 | 13.41 | 12.11 | 12.22 | 8.76 |
Pre Tax Margin(%) | 16.10 | 13.05 | 11.75 | 11.66 | 8.03 |
PAT Margin (%) | 11.73 | 9.17 | 8.61 | 8.51 | 5.70 |
Cash Profit Margin (%) | 14.70 | 12.95 | 12.15 | 12.29 | 10.03 |
Performance Ratios | |||||
ROA(%) | 13.59 | 10.19 | 9.94 | 9.95 | 6.56 |
ROE(%) | 16.63 | 12.85 | 13.10 | 14.13 | 10.09 |
ROCE(%) | 22.77 | 18.19 | 17.24 | 17.85 | 12.53 |
Asset Turnover(x) | 1.16 | 1.11 | 1.15 | 1.17 | 1.15 |
Sales/Fixed Asset(x) | 2.00 | 1.81 | 1.82 | 1.85 | 1.89 |
Working Capital/Sales(x) | 2.50 | 2.63 | 3.03 | 3.29 | 3.71 |
Efficiency Ratios | |||||
Fixed Capital/Sales(x) | 0.50 | 0.55 | 0.55 | 0.54 | 0.53 |
Receivable days | 45.49 | 44.13 | 42.19 | 47.44 | 54.10 |
Inventory Days | 53.56 | 61.98 | 61.53 | 58.49 | 56.12 |
Payable days | 103.64 | 111.52 | 98.28 | 107.95 | 128.84 |
Valuation Parameters | |||||
PER(x) | 29.28 | 25.95 | 32.65 | 27.34 | 22.05 |
PCE(x) | 23.18 | 18.14 | 22.75 | 18.95 | 12.53 |
Price/Book(x) | 4.53 | 3.11 | 3.95 | 3.60 | 2.17 |
Yield(%) | 0.87 | 0.94 | 0.49 | 0.61 | 0.95 |
EV/Net Sales(x) | 4.66 | 3.15 | 3.72 | 3.45 | 2.10 |
EV/Core EBITDA(x) | 17.06 | 13.02 | 16.77 | 14.63 | 10.12 |
EV/EBIT(x) | 20.73 | 17.27 | 22.52 | 19.16 | 15.12 |
EV/CE(x) | 4.45 | 2.99 | 3.74 | 2.66 | 1.93 |
M Cap / Sales | 4.68 | 3.19 | 3.78 | 3.43 | 1.99 |
Growth Ratio | |||||
Net Sales Growth(%) | 13.28 | 4.55 | 13.59 | 11.84 | 4.70 |
Core EBITDA Growth(%) | 27.90 | 13.83 | 6.98 | 27.27 | -0.66 |
EBIT Growth(%) | 39.63 | 15.23 | 4.31 | 45.26 | 5.69 |
PAT Growth(%) | 46.55 | 10.78 | 6.59 | 55.23 | 2.48 |
EPS Growth(%) | 47.06 | 11.28 | 4.61 | 55.46 | 1.16 |
Financial Stability Ratios | |||||
Total Debt/Equity(x) | 0.01 | 0.02 | 0.04 | 0.10 | 0.18 |
Current Ratio(x) | 3.70 | 3.34 | 2.99 | 2.87 | 2.66 |
Quick Ratio(x) | 2.70 | 2.31 | 1.91 | 1.85 | 1.67 |
Interest Cover(x) | 64.44 | 37.87 | 33.85 | 21.47 | 12.04 |
Total Debt/Mcap(x) | - | 0.01 | 0.01 | 0.03 | 0.08 |
Compare Financial Ratios of peers of CIPLA
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
CIPLA | ₹119,331.0 Cr | -2% | -7.7% | 23.2% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹433,032.0 Cr | -0.2% | 0.1% | 47% | Stock Analytics | |
DIVIS LABORATORIES | ₹162,735.0 Cr | -1.9% | 5.5% | 60.6% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹104,606.0 Cr | 2.6% | -1.5% | 7.9% | Stock Analytics | |
MANKIND PHARMA | ₹103,575.0 Cr | -1.2% | -4.8% | 36.6% | Stock Analytics | |
ZYDUS LIFESCIENCES | ₹100,100.0 Cr | 2.1% | 0.6% | 54.5% | Stock Analytics |
CIPLA Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
CIPLA | -2% |
-7.7% |
23.2% |
SENSEX | 2.4% |
3.7% |
21.1% |
You may also like the below Video Courses